FATE
HealthcareFate Therapeutics, Inc.
$1.01
+$0.02 (+2.02%)
Jan 5, 2026
Price History (1Y)
Analysis
Fate Therapeutics, Inc. is a biotechnology company operating in the healthcare sector. The company has a market capitalization of $116.51M and generates revenue of $7.14M (TTM), indicating a relatively small scale compared to larger industry players. With 181 employees, Fate Therapeutics maintains a moderate level of workforce size. The company's financial health is characterized by significant losses, with net income (TTM) totaling -$156,094,000 and an EBITDA of -$145,343,008. The operating margin stands at -1995.1%, while the profit margin is 0.0%. Additionally, Fate Therapeutics has a debt-to-equity ratio of 33.86 and cash holdings of $215.42M, indicating a substantial amount of liquidity. The company's valuation context features a forward P/E ratio of -0.87, suggesting significant volatility in earnings projections. The price to sales ratio is 16.32, while the EV/EBITDA stands at 0.15, highlighting concerns about profitability. Dividend information is not available for Fate Therapeutics.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $116.51M
- P/E Ratio
- N/A
- 52-Week High
- $1.94
- 52-Week Low
- $0.66
- Avg Volume
- 1.80M
- Beta
- 2.23
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 181